Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
Author:
Funder
Boehringer Ingelheim
Publisher
Elsevier BV
Reference30 articles.
1. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation;Bray;Obes Rev,2017
2. A review of current guidelines for the treatment of obesity;Cornier;Am J Manag Care,2022
3. 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) indications for metabolic and bariatric surgery;Eisenberg;Obes Surg,2023
4. Neural effects of gut- and brain-derived glucagon-like peptide-1 and its receptor agonist;Katsurada;J Diabetes Investig,2016
5. GLP-1 physiology informs the pharmacotherapy of obesity;Drucker;Mol Metab,2022
Cited by 23 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Survodutide, a new horizon in the treatment of obesity and Type 2 diabetes mellitus: A narrative review;Yemen Journal of Medicine;2024-09-15
2. Obesity in adults;The Lancet;2024-09
3. GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review;eClinicalMedicine;2024-09
4. Medications for Obesity;JAMA;2024-08-20
5. GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management;Nature Metabolism;2024-08-19
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3